2.01
+11.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Longeveron
From its filings with the US Securities and Exchange Commission
Longeveron is based in Miami, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LGVN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.2m and a net loss of $22.7m. At that date it held total assets of $10.3m and shareholders' equity of $5.7m. By business, Clinical Trial Revenue Member brought in 79.6% of revenue, followed by Contract Manufacturing Revenue Member at 18.5% and Contract Manufacturing Lease Revenue [Member] at 1.9%.
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas. Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.
Since our founding in 2014, we have focused the majority of our time and resources on the following: organizing and staffing our company, building, staffing and equipping a current good manufacturing practice (“cGMP”) manufacturing facility with research and development labs, business planning, raising capital, establishing and maintaining our intellectual property portfolio, generating clinical safety and efficacy data in our selected disease conditions and indications, and developing and expanding our manufacturing processes and capabilities to support both internal and external development programs.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 2021
- Employees
- 19
- Website
- longeveron.com ↗
- Head office
- 1951 NW 7TH AVENUE, MIAMI, FL, 33136
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Joshua HareExecutive Chairman of the Board, Co-Founder, Chief Science Officer, since 2014$640,393
- Mr. Than PowellInterim Chief Executive Officer
- Ms. Lisa LocklearChief Financial Officer, Treasurer$1.1m
- Mr. Devin BlassChief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
- Mr. Paul LehrGeneral Counsel and Secretary$1.2m
- Dr. Nataliya AgafonovaChief Medical Officer
- Dr. George PalettaDirector
- Mr. Rock SofferDirector$101,560
- Mr. Khoso BaluchIndependent Director$120,310
- Dr. Roger HajjarIndependent Director$56,255
- Mr. Richard KenderIndependent Director$60,226
- Ms. Neha MotwaniIndependent Director$56,130
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lomecel-B therapy derived from young donor bone marrow sources.
- Multiple mechanisms of action for pro-vascular and anti-inflammatory effects.
- Bone marrow supply contracts with Oklahoma Blood Institute and Vista Health Research.
Weaknesses
- 19 full-time employees limit operational capacity and scale.
- Clinical stage biotechnology company with limited pipeline indications.
- IPO listing date of 12 February 2021 shows recent market entry.
Opportunities
- Expanding applications for Lomecel-B across aging related frailty and Alzheimer's disease.
- Growing focus on biotechnology in the Health Care sector.
- Potential for new partnerships in the US biotechnology market.
Threats
- Competition from other biotechnology firms in the Health Care sector.
- Regulatory challenges in clinical stage biotechnology development.
- Dependence on bone marrow supply contracts for product development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.